Seeing Is Believing
Currently out of the existing stock ratings of James Quigley, 29 are a HOLD (67.44%), 12 are a BUY (27.91%), 2 are a SELL (4.65%).
Analyst James Quigley, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 59.28% that have a potential upside of 39.48% achieved within 170 days.
James Quigley’s has documented 79 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KYMR, Kymera Therapeutics at 06-Nov-2024.
Analyst best performing recommendations are on KYMR (KYMERA THERAPEUTICS).
The best stock recommendation documented was for KYMR (KYMERA THERAPEUTICS) at 11/13/2023. The price target of $24 was fulfilled within 30 days with a profit of $9.02 (60.21%) receiving and performance score of 20.07.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$17
$-1.96 (-10.34%)
$17
9 months 16 days ago
(05-Feb-2024)
3/3 (100%)
$-0.27 (-1.56%)
96
Hold
$9.2
10 months 5 days ago
(16-Jan-2024)
4/10 (40%)
$2.7 (41.54%)
490
Buy
$8.5
$-10.46 (-55.17%)
$10
11 months 16 days ago
(05-Dec-2023)
3/7 (42.86%)
$0.92 (12.14%)
253
Buy
$8.5
$-10.46 (-55.17%)
$10
11 months 16 days ago
(05-Dec-2023)
2/2 (100%)
$0.92 (12.14%)
106
Hold
$4.75
$-13.1 (-73.39%)
11 months 30 days ago
(22-Nov-2023)
1/2 (50%)
$0.2 (4.40%)
5
Which stock is James Quigley is most bullish on?
Which stock is James Quigley is most reserved on?
What Year was the first public recommendation made by James Quigley?